Lumanity will be presenting during the 2025 BioXconomy Digital Week.
Presentation:
Closing the Books Strong: Q4 Biopharma Deal Landscape and 2025 Outlook
October 1, 2025 | 10:00-10:55 am
As the biopharma industry navigates the final quarter of a transformative year, strategic dealmaking and investment patterns offer critical signals for what lies ahead. This exclusive thought leadership session provides senior executives with actionable intelligence at a pivotal moment in the industry calendar. Join Tim Opler, Managing Director at Stifel, as he delivers incisive market analysis through a dynamic fireside discussion. Drawing on his extensive experience in life sciences investment banking, Opler will decode Q4 activity patterns and translate them into strategic foresight for the coming year.
Session Highlights:
- Late-Year Deal Momentum: Uncover emerging patterns in Q4 partnering and M&A transactions that signal strategic priorities for industry leaders
- Capital Markets Pulse: Gain perspective on investor sentiment, valuation trends, and how financing conditions are reshaping deal structures
- Big Pharma’s Strategic Pivot: Examine how portfolio gaps and pipeline evolution are driving new approaches to external innovation
- 2025 Dealmaking Calendar: Identify key inflection points and opportunities to watch as you plan your engagement strategy for BIO-Europe and beyond
Presenters:
– Tim Opler, Managing Director, Stifel (Moderator)
– Nick Downing, Managing Director, Life Sciences, Bain Capital
– Fiona MacLaughlin, Senior Director, Johnson & Johnson Innovation, JJDC Inc.
– Maha Radhakrishnan, Executive Partner, Sofinnova Investments
– Jim Robertson, CEO, Nu-Life Solutions
– Ed Saltzman, Senior Strategic Advisor, Lumanity
– Laura Tadvalkar, Managing Director, RA Capital
Reach out to Ed Saltzman directly to set up a meeting, or email contact@lumanity.com.
